Nausea, vomiting, and retching are common and distressing complaints: surveys have found that 50-60% of patients with advanced cancer suffer from one or more of these. These symptoms are more common in patients under 65 years old, in women, and in those with cancer of the stomach or breast.
As well as the specific causes of vomiting resulting directly or indirectly from advanced malignancy, patients may develop unrelated conditions such as gastroenteritis or gall bladder disease. In most cases the cause of vomiting is multifactorial, but it is helpful in planning treatment to list all contributing factors.
The causes of vomiting can usually be determined from a careful history and clinical examination. Note should be taken of the volume, content, and timing of vomits. A biochemical profile may be needed, but other investigations are often inappropriate.
Management
Common causes of vomiting in patients with advanced cancer Nausea can be treated with oral drugs, but alternative routes are needed for patients with severe vomiting. It must be remembered, however, that persistent nausea may decrease gastric emptying, with a resultant decrease in drug absorption. An antiemetic injection is suitable to control a single episode, but with a persistent problem it is preferable to give drugs by subcutaneous infusion using an infusion device such as a pocket sized syringe driver. Antiemetics, in suppository or tablet form, can also be given rectally, but buccal administration of antiemetics is poorly tolerated.
Non-drug methods are important; these include avoidance of food smells or unpleasant odours, diversion, and relaxation. Some patients report benefit from acupuncture or acupressure bands.
Specific cause of vomiting
In a few patients, a specific cause of vomiting can be identified and treated successfully. However, most patients have irreversible and multiple causes of vomiting and require treatment with antiemetics and other measures. Inoperable gastroduodenal obstruction-Metoclopramide may be effective if the obstruction is partial. Dexamethasone was thought to shrink inflammatory oedema around an obstructive lesion, but it may work by reducing perineuronal oedema in a functional obstruction; its antiemetic effect may also be of benefit. Octreotide or high dose hyoscine butylbromide may reduce the volume of vomit, otherwise intubation will be required.
Raised intracranial pressure-If dexamethasone is contraindicated or ineffective, cyclizine is the antiemetic of choice.
Vestibular disturbance-Cyclizine is usually effective, but an alternative is sublingual or transdermal hyoscine hydrobromide.
Intestinal obstruction
Intestinal obstruction is caused by an occlusion to the lumen or a lack of normal propulsion that prevents or delays intestinal contents from passing along the gastrointestinal tract. Obstruction may cause the presenting symptoms of cancer, or may develop during the course of the disease. Any site in the bowel may be affected, from the gastroduodenal junction to the rectum and anus.
While surgery remains the primary treatment for malignant obstruction, it is now recognised that some patients with advanced disease or poor general condition are unfit for surgery and require alternative management to relieve distressing symptoms.
Aetiology
The overall incidence of intestinal obstruction in patients with advanced cancer is about 3%, but patients with advanced ovarian cancer have a risk of obstruction of 25-40%. Patients with metastatic abdominal or pelvic cancer often have both mechanical and functional causes for obstruction, which may occur at more than one site.
Causes of intestinal obstruction in advanced cancer
• Extrinsic compression from enlargement of primary tumour, omental masses, malignant adhesions, post-irradiation fibrosis • Intraluminal occlusion from annular tumour or polypoid lesions 
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Clinical features
The symptoms of intestinal obstruction will depend on the site of the problem, a high obstruction causing more severe vomiting. In patients with advanced disease the onset of obstruction is usually insidious, over some weeks. Symptoms may gradually worsen and become continuous, but even without treatment the symptoms may be intermittent and the obstructive episodes resolve spontaneously, if temporarily.
A distinction is often made between complete and partial obstruction, but this is far from easy in practice and, clinically, the obstruction may seem to alter from one type to the other on several occasions as the illness progresses.
Investigations
Radiological investigations are of value in only two clinical situations: firstly, to differentiate between constipation and malignant obstruction; and, secondly, to confirm the obstruction and determine its site and nature in a patient who is being considered for surgery.
Management
There are now several treatment options for patients with advanced cancer who develop intestinal obstruction. It is rarely an emergency, so there is usually time to discuss the situation with patients and their family so that they can make an informed choice of the available treatments. Palliative surgery should be considered for every patient with advanced cancer who develops intestinal obstruction. Some will have a non-malignant cause or an unrelated second primary tumour. However, mortality is high (12-30%), the mean survival time is short, and there is a high incidence of enterocutaneous fistulae.
Symptoms of intestinal obstruction
Nasogastric intubation
This leads to a sustained relief of obstruction in only 0-2% of patients. It should therefore be used only for patients who are being considered for surgery and for those, principally with a high obstruction, who respond poorly to drug treatment. In this group, percutaneous venting gastrostomy should be considered as a better tolerated alternative. This can be performed under local anaesthesia. Drugs have been used for years to relieve symptoms, and treatment regimens have gradually evolved. Continuous subcutaneous infusion is the preferred route of drug administration. This allows a combination of drugs to be given, and it is ideal for use in the home as it can be renewed every 24 hours by the visiting nurse.
The symptoms of colic, continuous abdominal pain, and vomiting usually occur together, and a typical starting prescription would be
• Diamorphine (dose depending on previous opioid dose)
• Hyoscine butylbromide 60 mg/24 hours • Haloperidol 5 mg/24 hours.
If continuous pain or colic is not controlled, the dose of diamorphine or hyoscine butylbromide should be increased. If nausea and vomiting remain problems, cyclizine can be substituted for haloperidol or the two drugs can be used in combination. A useful alternative to this is methotrimeprazine, a highly effective antiemetic in this situation. However, if this fails, and especially if the total volume of vomits is large, octreotide is often used. It is antisecretory, proabsorbtive, and reduces forward peristalsis. It can be combined with other drugs for subcutaneous infusion.
Corticosteroids have been widely used with apparent benefit to individual patients, but, with the intermittent nature of the early symptoms, it is difficult to know if the improvement is due to the corticosteroid treatment.
All patients will need regular mouth care. With good or moderate control of nausea and vomiting, patients can eat and drink as they choose, most favouring small and low residue meals. A small group of patients, mainly with high obstruction, continue to vomit profusely in spite of medication. These may benefit from the insertion of a nasogastric tube or venting gastrostomy. The need for parenteral hydration should be decided on an individual basis; if indicated, fluids can be given by intravenous infusion or by hypodermoclysis (subcutaneous fluids). This is well tolerated and can be administered in the home supervised by the family and community nursing staff.
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